Prelude Therapeutics Inc Financials

PRLD

Export CSV

Key Financial Metrics

Revenue

$7.0M

Prelude Therapeutics Inc generated $7.0M in revenue in fiscal year 2024.

EBITDA

-$137.9M

YoY-5.2%

Prelude Therapeutics Inc's EBITDA was -$137.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.2% from the prior year.

Free Cash Flow

-$103.7M

YoY+6.3%

Prelude Therapeutics Inc generated -$103.7M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents an increase of 6.3% from the prior year.

Net Income

-$127.2M

YoY-4.4%

Prelude Therapeutics Inc reported -$127.2M in net income in fiscal year 2024. This represents a decrease of 4.4% from the prior year.

EPS (Diluted)

$-1.68

YoY+16.8%

Prelude Therapeutics Inc earned $-1.68 per diluted share in fiscal year 2024. This represents an increase of 16.8% from the prior year.

Cash & Debt

$12.5M

YoY-50.7%

5Y CAGR-8.0%

Prelude Therapeutics Inc held $12.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Gross Margin

N/A

Operating Margin

-1995.9%

Prelude Therapeutics Inc's operating margin was -1995.9% in fiscal year 2024, reflecting core business profitability.

Net Margin

-1816.8%

Prelude Therapeutics Inc's net profit margin was -1816.8% in fiscal year 2024, showing the share of revenue converted to profit.

Return on Equity

N/A

R&D Spending

$118.0M

YoY+14.1%

5Y CAGR+37.2%

Prelude Therapeutics Inc invested $118.0M in research and development in fiscal year 2024. This represents an increase of 14.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$764K

YoY-78.3%

5Y CAGR-0.4%

Prelude Therapeutics Inc invested $764K in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 78.3% from the prior year.

PRLD Income Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Revenue	$7.0M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$118.0M+14.1%	$103.4M+11.3%	$92.9M+7.0%	$86.8M+80.1%	$48.2M+98.4%	$24.3M
SG&A Expenses	$28.7M-0.6%	$28.9M-5.8%	$30.7M+13.7%	$27.0M+154.6%	$10.6M+176.4%	$3.8M
Operating Income	-$139.7M-5.6%	-$132.3M-7.1%	-$123.5M-8.6%	-$113.7M-93.5%	-$58.8M-109.1%	-$28.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$127.2M-4.4%	-$121.8M-5.5%	-$115.4M-3.4%	-$111.7M-96.2%	-$56.9M-106.5%	-$27.6M
EPS (Diluted)	$-1.68+16.8%	$-2.02+17.2%	$-2.44-0.4%	$-2.43	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Revenue	$6.5M	N/A	N/A	N/A	$3.0M	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$21.7M-15.8%	$25.8M-10.5%	$28.8M	N/A	$29.5M-0.2%	$29.5M+7.7%	$27.4M	N/A
SG&A Expenses	$5.2M-18.7%	$6.4M+10.7%	$5.8M	N/A	$7.9M+3.4%	$7.7M+10.4%	$6.9M	N/A
Operating Income	-$20.4M+36.6%	-$32.2M+7.0%	-$34.6M	N/A	-$34.4M+7.5%	-$37.2M-8.2%	-$34.3M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$19.7M+36.8%	-$31.2M+2.7%	-$32.1M	N/A	-$32.3M+7.1%	-$34.7M-10.5%	-$31.4M	N/A
EPS (Diluted)	$-0.26+36.6%	$-0.41+2.4%	$-0.42	N/A	$-0.43+6.5%	$-0.46-9.5%	$-0.42	N/A

PRLD Balance Sheet

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Total Assets	$175.5M-36.8%	$277.7M+25.9%	$220.5M-27.7%	$305.1M+36.5%	$223.6M+922.3%	$21.9M
Current Assets	$135.9M-42.3%	$235.6M+15.3%	$204.4M-30.7%	$295.1M+33.7%	$220.8M+991.8%	$20.2M
Cash & Equivalents	$12.5M-50.7%	$25.3M-17.4%	$30.6M-3.8%	$31.8M-85.4%	$218.3M+1056.4%	$18.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$44.1M+8.6%	$40.6M+61.9%	$25.1M+30.5%	$19.2M+68.3%	$11.4M-84.0%	$71.3M
Current Liabilities	$25.6M+17.5%	$21.8M+0.6%	$21.7M+13.0%	$19.2M+68.8%	$11.4M+135.3%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$131.5M-44.6%	$237.1M+21.3%	$195.4M-31.6%	$285.9M+34.7%	$212.2M+529.4%	-$49.4M
Retained Earnings	-$583.6M-27.9%	-$456.4M-36.4%	-$334.6M-52.7%	-$219.1M-104.0%	-$107.4M-112.7%	-$50.5M

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Total Assets	$94.8M-17.5%	$114.9M-18.6%	$141.3M-19.5%	$175.5M-11.0%	$197.2M-12.1%	$224.3M-9.2%	$247.1M-11.0%	$277.7M
Current Assets	$58.3M-24.1%	$76.9M-24.9%	$102.4M-24.6%	$135.9M-13.1%	$156.4M-14.4%	$182.7M-11.0%	$205.4M-12.8%	$235.6M
Cash & Equivalents	$47.5M+84.6%	$25.8M-36.1%	$40.3M+222.8%	$12.5M+12.0%	$11.1M-60.0%	$27.8M+12.6%	$24.7M-2.3%	$25.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$36.2M-7.3%	$39.1M+2.6%	$38.1M-13.6%	$44.1M+8.0%	$40.8M-2.9%	$42.0M+15.5%	$36.4M-10.4%	$40.6M
Current Liabilities	$18.2M-13.0%	$20.9M+5.7%	$19.8M-22.8%	$25.6M+15.4%	$22.2M-4.8%	$23.3M+32.3%	$17.6M-19.2%	$21.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$58.5M-22.8%	$75.8M-26.5%	$103.2M-21.5%	$131.5M-16.0%	$156.4M-14.2%	$182.3M-13.5%	$210.7M-11.1%	$237.1M
Retained Earnings	-$666.6M-3.0%	-$646.9M-5.1%	-$615.6M-5.5%	-$583.6M-5.2%	-$554.8M-6.2%	-$522.6M-7.1%	-$487.8M-6.9%	-$456.4M

PRLD Cash Flow Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$102.9M+3.9%	-$107.1M-27.9%	-$83.7M-0.2%	-$83.5M-80.9%	-$46.2M-79.9%	-$25.7M
Capital Expenditures	$764K-78.3%	$3.5M+16.4%	$3.0M+30.0%	$2.3M+274.1%	$621K-20.4%	$780K
Free Cash Flow	-$103.7M+6.3%	-$110.6M-27.5%	-$86.7M-1.0%	-$85.9M-83.5%	-$46.8M-77.0%	-$26.4M
Investing Cash Flow	$90.2M+360.3%	-$34.6M-142.4%	$81.7M+131.0%	-$263.8M-42380.4%	-$621K+20.4%	-$780K
Financing Cash Flow	-$120K-100.1%	$136.4M+16635.6%	$815K-99.5%	$164.9M-33.0%	$246.2M+728.2%	$29.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Operating Cash Flow	N/A	N/A	-$34.2M	N/A	N/A	N/A	-$31.8M	N/A
Capital Expenditures	N/A	N/A	$47K	N/A	N/A	N/A	$289K	N/A
Free Cash Flow	N/A	N/A	-$34.3M	N/A	N/A	N/A	-$32.1M	N/A
Investing Cash Flow	N/A	N/A	$62.2M	N/A	N/A	N/A	$31.2M	N/A
Financing Cash Flow	N/A	N/A	-$160K	N/A	N/A	N/A	-$14K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PRLD Financial Ratios

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1995.9%	N/A	N/A	N/A	N/A	N/A
Net Margin	-1816.8%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-72.5%-28.6pp	-43.9%+8.5pp	-52.3%-15.7pp	-36.6%-11.1pp	-25.5%+100.6pp	-126.1%
Current Ratio	5.30-5.5	10.79+1.4	9.42-6.0	15.37-4.0	19.41+15.2	4.18
Debt-to-Equity	0.34+0.2	0.17+0.0	0.13+0.1	0.07+0.0	0.05+1.5	-1.44
FCF Margin	-1480.7%	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-314.1%	N/A	N/A	N/A	-1145.9%	N/A	N/A	N/A
Net Margin	-303.5%	N/A	N/A	N/A	-1075.7%	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-20.8%+6.4pp	-27.2%-4.5pp	-22.7%	N/A	-16.4%-0.9pp	-15.5%-2.8pp	-12.7%	N/A
Current Ratio	3.21-0.5	3.68-1.5	5.18-0.1	5.30-1.7	7.04-0.8	7.83-3.8	11.64+0.8	10.79
Debt-to-Equity	0.62+0.1	0.52+0.1	0.37+0.0	0.34+0.1	0.26+0.0	0.23+0.1	0.170.0	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is Prelude Therapeutics Inc's annual revenue?

Prelude Therapeutics Inc (PRLD) reported $7.0M in revenue for fiscal year 2024.

Is Prelude Therapeutics Inc profitable?

No, Prelude Therapeutics Inc (PRLD) reported a net income of -$127.2M in fiscal year 2024, with a net profit margin of -1816.8%.

What is Prelude Therapeutics Inc's earnings per share (EPS)?

Prelude Therapeutics Inc (PRLD) reported diluted earnings per share of $-1.68 for fiscal year 2024.

What is Prelude Therapeutics Inc's EBITDA?

Prelude Therapeutics Inc (PRLD) had EBITDA of -$137.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Prelude Therapeutics Inc's operating margin?

Prelude Therapeutics Inc (PRLD) had an operating margin of -1995.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Prelude Therapeutics Inc's net profit margin?

Prelude Therapeutics Inc (PRLD) had a net profit margin of -1816.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Prelude Therapeutics Inc's free cash flow?

Prelude Therapeutics Inc (PRLD) generated -$103.7M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Prelude Therapeutics Inc's operating cash flow?

Prelude Therapeutics Inc (PRLD) generated -$102.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Prelude Therapeutics Inc's total assets?

Prelude Therapeutics Inc (PRLD) had $175.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Prelude Therapeutics Inc's capital expenditures?

Prelude Therapeutics Inc (PRLD) invested $764K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Prelude Therapeutics Inc spend on research and development?

Prelude Therapeutics Inc (PRLD) invested $118.0M in research and development during fiscal year 2024.

What is Prelude Therapeutics Inc's current ratio?

Prelude Therapeutics Inc (PRLD) had a current ratio of 5.30 as of fiscal year 2024, which is generally considered healthy.

What is Prelude Therapeutics Inc's debt-to-equity ratio?

Prelude Therapeutics Inc (PRLD) had a debt-to-equity ratio of 0.34 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Prelude Therapeutics Inc's return on assets (ROA)?

Prelude Therapeutics Inc (PRLD) had a return on assets of -72.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.